Lineage Cell Therapeutics Inc Total Liabilities
Lineage Cell Therapeutics Inc total liabilities. Based on the latest financial reports, Lineage Cell Therapeutics Inc (LCTX) has total liabilities worth $68.84 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Lineage Cell Therapeutics Inc's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Lineage Cell Therapeutics Inc (1991–2024)
Total liabilities of Lineage Cell Therapeutics Inc from 1991 to 2024. This chart illustrates how Lineage Cell Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Lineage Cell Therapeutics Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
Lineage Cell Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Lineage Cell Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Colonial Coal International Corp
V:CAD
|
Canada | CA$106.36K |
|
Transcontinental Inc
TO:TCL-A
|
Canada | CA$815.10 Million |
|
Shenzhen Kexin Communication Technologies Co Ltd
SHE:300565
|
China | CN¥848.80 Million |
|
Websol Energy System Limited
NSE:WEBELSOLAR
|
India | Rs3.17 Billion |
|
Dalian Friendship Group Co Ltd
SHE:000679
|
China | CN¥934.44 Million |
|
Shanghai Kaichuang Marine International Co Ltd
SHG:600097
|
China | CN¥1.05 Billion |
|
Ernst Russ AG
XETRA:ERAG
|
Germany | €77.27 Million |
|
Hyliion Holdings Corp.
NYSE:HYLN
|
USA | $12.38 Million |
Liability Composition Analysis (1991–2024)
This chart breaks down Lineage Cell Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Lineage Cell Therapeutics Inc assets under control.
Liquidity & Leverage Metrics
Lineage Cell Therapeutics Inc Total Liabilities Ratios Explained
Lineage Cell Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.50 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.77 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lineage Cell Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lineage Cell Therapeutics Inc (1991–2024)
The table below shows the annual total liabilities of Lineage Cell Therapeutics Inc from 1991 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $36.21 Million | -7.15% |
| 2023-12-31 | $39.00 Million | -24.61% |
| 2022-12-31 | $51.73 Million | -38.16% |
| 2021-12-31 | $83.65 Million | +552.37% |
| 2020-12-31 | $12.82 Million | -9.90% |
| 2019-12-31 | $14.23 Million | +51.17% |
| 2018-12-31 | $9.41 Million | +4.86% |
| 2017-12-31 | $8.98 Million | -25.58% |
| 2016-12-31 | $12.06 Million | -33.76% |
| 2015-12-31 | $18.21 Million | +49.55% |
| 2014-12-31 | $12.18 Million | -21.27% |
| 2013-12-31 | $15.47 Million | +183.59% |
| 2012-12-31 | $5.45 Million | +24.77% |
| 2011-12-31 | $4.37 Million | +13.63% |
| 2010-12-31 | $3.85 Million | +61.23% |
| 2009-12-31 | $2.39 Million | -55.67% |
| 2008-12-31 | $5.38 Million | +67.07% |
| 2007-12-31 | $3.22 Million | +28.05% |
| 2006-12-31 | $2.52 Million | +16.72% |
| 2005-12-31 | $2.16 Million | +83.15% |
| 2004-12-31 | $1.18 Million | -66.40% |
| 2003-12-31 | $3.50 Million | +31.30% |
| 2002-12-31 | $2.67 Million | +30.72% |
| 2001-12-31 | $2.04 Million | +467.19% |
| 2000-12-31 | $359.75K | -39.59% |
| 1999-12-31 | $595.51K | +48.88% |
| 1998-12-31 | $400.00K | -77.78% |
| 1997-12-31 | $1.80 Million | +800.00% |
| 1996-12-31 | $200.00K | 0.00% |
| 1995-12-31 | $200.00K | -50.00% |
| 1994-12-31 | $400.00K | +300.00% |
| 1993-12-31 | $100.00K | 0.00% |
| 1992-12-31 | $100.00K | -50.00% |
| 1991-12-31 | $200.00K | -- |
About Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; OPC1, an allogeneic… Read more